Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: Long-term follow-up of a prospective, randomised, multicentre trial

The Lancet Oncology

Volumn 11, Issue 10, 2010, Pages 950-961

  Lipshultz, Steven E ^a,b,c   Scully, Rebecca E ^a,b,c   Lipsitz, Stuart R ^d   Sallan, Stephen E ^e,o   Silverman, Lewis B ^e,o   Miller, Tracie L ^a,b,c   Barry, Elly V ^f   Asselin, Barbara L ^g   Athale, Uma ^h   Clavell, Luis A ⁱ   Larsen, Eric ^j   Moghrabi, Albert ^k   Samson, Yvan ^l   Michon, Bruno ^l   Schorin, Marshall A ^m   Cohen, Harvey J ⁿ   Neuberg, Donna S ^e   Orav, E John ^d   Colan, Steven D ^o  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b JACKSON MEMORIAL HOSPITAL   (United States)

^c UNIVERSITY OF MIAMI   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e DANA FARBER CANCER INSTITUTE   (United States)

^f GENZYME CORPORATION   (United States)

^g UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^h MCMASTER UNIVERSITY   (Canada)

ⁱ San Jorge Children's Hospital   (Puerto Rico)

^j Maine Children's Cancer Program Portland   (United States)

^k UNIVERSITY OF MONTREAL   (Canada)

^l LAVAL UNIVERSITY   (Canada)

^m INOVA FAIRFAX HOSPITAL FOR CHILDREN   (United States)

ⁿ STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^o BOSTON CHILDREN S HOSPITAL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; RAZOXANE; TROPONIN T; ANTINEOPLASTIC ANTIBIOTIC; BIOLOGICAL MARKER; CARDIOVASCULAR AGENT;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; BOLUS INJECTION; CANADA; CANCER MORTALITY; CHILD; CHILDHOOD LEUKEMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG RESPONSE; ECHOCARDIOGRAPHY; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE CONTRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; HIGH RISK PATIENT; HUMAN; LEUKEMIA REMISSION; LONG TERM CARE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PUERTO RICO; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SEX DIFFERENCE; SURVIVOR; UNITED STATES; ADOLESCENT; BLOOD; CARDIOMYOPATHIES; CHEMICALLY INDUCED; DISEASE FREE SURVIVAL; DRUG EFFECTS; ECHOGRAPHY; HEART CONTRACTION; KAPLAN MEIER METHOD; MORTALITY; PATHOPHYSIOLOGY; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; TIME; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ANTIBIOTICS, ANTINEOPLASTIC; BIOLOGICAL MARKERS; CANADA; CARDIOMYOPATHIES; CARDIOVASCULAR AGENTS; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MYOCARDIAL CONTRACTION; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROSPECTIVE STUDIES; PUERTO RICO; RAZOXANE; RISK ASSESSMENT; RISK FACTORS; SURVIVORS; TIME FACTORS; TREATMENT OUTCOME; TROPONIN T; UNITED STATES; VENTRICULAR FUNCTION, LEFT; YOUNG ADULT; KAPLAN-MEIER ESTIMATE;

EID: 77957355941     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(10)70204-7     Document Type: Article

References (91)

1. Moghrabi A, Levy DE, Asselin B, et al. Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. Blood 2007, 109:896-904.
2. Silverman LB, Gelber RD, Dalton VK, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood 2001, 97:1211-1218.
3. Schrappe M, Reiter A, Ludwig WD, et al. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group. Blood 2000, 95:3310-3322.
4. Pui CH, Campana D, Pei D, et al. Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med 2009, 360:2730-2741.
5. Gaynon PS, Trigg ME, Heerema NA, et al. Children's Cancer Group trials in childhood acute lymphoblastic leukemia: 1983-1995. Leukemia 2000, 14:2223-2233.
6. Hewitt M, Weiner SL, Simone JV Childhood cancer survivorship: improving care and quality of life 2003, 1-14. The National Academies Press, Washington, DC.
7. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008, 58:71-96.
8. Geenen MM, Cardous-Ubbink MC, Kremer LC, et al. Medical assessment of adverse health outcomes in long-term survivors of childhood cancer. JAMA 2007, 297:2705-2715.
9. Lipshultz SE, Colan SD, Gelber RD, Perez-Atayde AR, Sallan SE, Sanders SP Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 1991, 324:808-815.
10. Lipshultz SE, Lipsitz SR, Mone SM, et al. Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med 1995, 332:1738-1743.
11. Lipshultz SE, Lipsitz SR, Sallan SE, et al. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J Clin Oncol 2005, 23:2629-2636.
12. Oeffinger KC, Mertens AC, Sklar CA, et al. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med 2006, 355:1572-1582. for the Childhood Cancer Survivor Study.
13. Armstrong GT, Liu O, Yasui Y, et al. Late mortality among 5-year survivors of childhood cancer: a summary from the Childhood Cancer Survivor Study. J Clin Oncol 2009, 27:2328-2338.
14. Mertens AC, Yasui Y, Neglia JP, et al. Late mortality experience in five-year survivors of childhood and adolescent cancer: the Childhood Cancer Survivor Study. J Clin Oncol 2001, 19:3163-3172.
15. Möller TR, Garwicz S, Barlow L, et al. Decreasing late mortality among five-year survivors of cancer in childhood and adolescence: a population-based study in the Nordic countries. J Clin Oncol 2001, 19:3173-3181. for the Association of the Nordic Cancer Registries and the Nordic Society for Pediatric Hematology and Oncology.
16. Mulrooney DA, Yeazel MW, Kawashima T, et al. Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort. BMJ 2009, 339:b4606.
17. Tukenova M, Guibout C, Oberlin O, et al. Role of cancer treatment in long-term overall and cardiovascular mortality after childhood cancer. J Clin Oncol 2010, 28:1308-1315.
18. Lipshultz SE, Adams MJ Cardiotoxicity after childhood cancer: beginning with the end in mind. J Clin Oncol 2010, 28:1276-1281.
19. Reulen RC, Winter DL, Frobisher C, et al. Long-term cause-specific mortality among survivors of childhood cancer. JAMA 2010, 304:172-179. for the British Childhood Cancer Survivor Study Steering Group.
20. Levitt G, Anazodo A, Burch M, Bunch K Cardiac or cardiopulmonary transplantation in childhood cancer survivors: an increasing need?. Eur J Cancer 2009, 45:3027-3034.
21. Lipshultz SE, Alvarez JA, Scully RE Anthracycline associated cardiotoxicity in survivors of childhood cancer. Heart 2008, 94:525-533.
22. Gianni L, Herman EH, Lipshultz SE, Minotti G, Sarvazyan N, Sawyer DB Anthracycline cardiotoxicity: from bench to bedside. J Clin Oncol 2008, 26:3777-3784.
23. Barry E, Alvarez JA, Scully RE, Miller TL, Lipshultz SE Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management. Expert Opin Pharmacother 2007, 8:1039-1058.
24. Wouters KA, Kremer LC, Miller TL, Herman EH, Lipshultz SE Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies. Br J Haematol 2005, 131:561-578.
25. Krischer JP, Epstein S, Cuthbertson DD, Goorin AM, Epstein ML, Lipshultz SE Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience. J Clin Oncol 1997, 15:1544-1552.
26. Lebrecht D, Geist A, Ketelsen UP, Haberstroh J, Setzer B, Walker UA Dexrazoxane prevents doxorubicin-induced long-term cardiotoxicity and protects myocardial mitochondria from genetic and functional lesions in rats. Br J Pharmacol 2007, 151:771-778.
27. Lipshultz SE, Walker VE, Torres SM, et al. Frequent mitochondrial DNA mutations and polymorphisms in long-term survivors of childhood acute lymphoblastic leukemia. Blood 2007, 118:824A. (abstr).
28. Lipshultz SE, Lipsitz SR, Sallan SE, et al. Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer. J Clin Oncol 2002, 20:4517-4522.
29. Lipshultz SE, Vlach SA, Lipsitz SR, Sallan SE, Schwartz ML, Colan SD Cardiac changes associated with growth hormone therapy in children treated with anthracyclines. Pediatrics 2005, 115:1613-1622.
30. Lipshultz SE, Giantris AL, Lipsitz SR, et al. Doxorubicin administration by continuous infusion is not cardioprotective: the Dana-Farber 91-01 Acute Lymphoblastic Leukemia protocol. J Clin Oncol 2002, 20:1677-1682.
31. Fernandez HF, Sun Z, Yao X, et al. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med 2009, 361:1249-1259.
32. Lipshultz SE, Rifai N, Dalton VM, et al. The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N Engl J Med 2004, 351:145-153.
33. Lipshultz SE Dexrazoxane for protection against cardiotoxic effects of anthracyclines in children. J Clin Oncol 1996, 14:328-331.
34. Barry EV, Vrooman LM, Dahlberg SE, et al. Absence of secondary malignant neoplasms in children with high-risk acute lymphoblastic leukemia treated with dexrazoxane. J Clin Oncol 2008, 26:1106-1111.
35. Herman EH, Zhang J, Rifai N, et al. The use of serum levels of cardiac troponin T to compare the protective activity of dexrazoxane against doxorubicin- and mitoxantrone-induced cardiotoxicity. Cancer Chemother Pharmacol 2001, 48:297-304.
36. Popelová O, Sterba M, Hasková P, et al. Dexrazoxane-afforded protection against chronic anthracycline cardiotoxicity in vivo: effective rescue of cardiomyocytes from apoptotic cell death. Br J Cancer 2009, 101:792-802.
37. Carvalho RA, Sousa RP, Cadete VJ, et al. Metabolic remodeling associated with subchronic doxorubicin cardiomyopathy. Toxicology 2010, 270:92-98.
38. Lipshultz SE, Rifai N, Sallan SE, et al. Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury. Circulation 1997, 96:2641-2648.
39. Colan SD, Parness IA, Spevak PJ, Sanders SP Developmental modulation of myocardial mechanics: age- and growth-related alterations in afterload and contractility. J Am Coll Cardiol 1992, 19:619-629.
40. Sluysmans T, Colan SD Theoretical and empirical derivation of cardiovascular allometric relationships in children. J Appl Physiol 2005, 99:445-457.
41. Lopez L, Colan SD, Frommelt PC, et al. Recommendations for quantification methods during the performance of a pediatric echocardiogram: a report from the Pediatric Measurements Writing Group of the American Society of Echocardiography Pediatric and Congenital Heart Disease Council. J Am Soc Echocardiogr 2010, 23:465-495.
42. Lipsitz SR, Fitzmaurice GM, Ibrahim JG, Gelber R, Lipshultz S Parameter estimation in longitudinal studies with outcome-dependent follow-up. Biometrics 2002, 58:621-630.
43. Schorin MA, Blattner S, Gelber RD, et al. Treatment of childhood acute lymphoblastic leukemia: results of Dana-Farber Cancer Institute/Children's Hospital Acute Lymphoblastic Leukemia Consortium Protocol 85-01. J Clin Oncol 1994, 12:740-747.
44. Nysom K, Holm K, Lipsitz SR, et al. Relationship between cumulative anthracycline dose and late cardiotoxicity in childhood acute lymphoblastic leukemia. J Clin Oncol 1998, 16:545-550.
45. Marty M, Espié M, Llombart A, et al. Multicenter randomized phase III study of the cardioprotective effect of dexrazoxane (Cardioxane) in advanced/metastatic breast cancer patients treated with anthracycline-based chemotherapy. Ann Oncol 2006, 17:614-622. for the Dexrazoxane Study Group.
46. Herman EH, Zhang J, Lipshultz SE, et al. Correlation between serum levels of cardiac troponin-T and the severity of the chronic cardiomyopathy induced by doxorubicin. J Clin Oncol 1999, 17:2237-2243.
47. 2 HIV) Study Group. Circulation 2000, 102:1542-1548.
48. 2 HIV) Study Group.
49. 2 HIV study. Circulation 2001, 104:310-316.
50. Pfeffer MA, Braunwald E Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation 1990, 81:1161-1172.
51. Cohn JN, Ferrari R, Sharpe N Cardiac remodeling-concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. J Am Coll Cardiol 2000, 35:569-582. on behalf of an International Forum on Cardic Remodeling.
52. Adamcová M, Potáčová A, Popelová O, et al. Cardiac remodeling and MMPs on the model of chronic daunorubicin-induced cardiomyopathy in rabbits. Physiol Res 2010, published online April 20.
53. Miller TL, Lipsitz SR, Lopez-Mitnik G, et al. Characteristics and determinants of adiposity in pediatric cancer survivors. Cancer Epidemiol Biomarkers Prev 2010, 19:2013-2022.
54. Armstrong GT, Sklar CA, Hudson MM, Robison LL Long-term health status among survivors of childhood cancer: does sex matter?. J Clin Oncol 2007, 25:4477-4489.
55. Pui CH, Boyett JM, Relling MV, et al. Sex differences in prognosis for children with acute lymphoblastic leukemia. J Clin Oncol 1999, 17:818-824.
56. Waber DP, Tarbell NJ, Kahn CM, Gelber RD, Sallan SE The relationship of sex and treatment modality to neuropsychologic outcome in childhood acute lymphoblastic leukemia. J Clin Oncol 1992, 10:810-817.
57. Oeffinger KC, Mertens AC, Sklar CA, et al. Obesity in adult survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. J Clin Oncol 2003, 21:1359-1365. for the Childhood Cancer Survivor Study.
58. Silber JH, Jakacki RI, Larsen RL, Goldwein JW, Barber G Increased risk of cardiac dysfunction after anthracyclines in girls. Med Pediatr Oncol 1993, 21:477-479.
59. Thompson PA, Rosner GL, Matthay KK, et al. Impact of body composition on pharmacokinetics of doxorubicin in children: a Glaser Pediatric Research Network study. Cancer Chemother Pharmacol 2009, 64:243-251.
60. Sparreboom A, Wolff AC, Mathijssen RH, et al. Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese. J Clin Oncol 2007, 25:4707-4713.
61. Schuetz EG, Furuya KN, Schuetz JD Interindividual variation in expression of P-glycoprotein in normal human liver and secondary hepatic neoplasms. J Pharmacol Exp Ther 1995, 275:1011-1018.
62. Belhani D, Fanton L, Vaillant F, et al. Cardiac lesions induced by testosterone: protective effects of dexrazoxane and trimetazindine. Cardiovasc Toxicol 2009, 9:64-69.
63. Hsoch EM, Piña IL Heart failure in women: a need for prospective data. J Am Coll Cardiol 2009, 54:491-498.
64. Lipshultz SE, Simbre VC, Hart S, et al. Frequency of elevations in markers of cardiomyocyte damage in otherwise healthy newborns. Am J Cardiol 2008, 102:761-766.
65. Seifert HA, Howard DL, Silber JH, Jobes DR Female gender increases the risk of death during hospitalization for pediatric cardiac surgery. J Thorac Cardiovasc Surg 2007, 133:668-675.
66. Lipshultz SE, Shearer WT, Thompson B, et al. Cardiac effects of antiretroviral therapy in HIV-negative infants born to HIV-positive mothers: the NHLBI CHAART-1 cohort study. J Am Coll Cardiol (in press).
67. Cardinale D, Sandri MT, Colombo A, et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation 2004, 109:2749-2754.
68. Lipshultz SE, Wilkinson JD, Messiah SE, Miller TL Clinical research directions in pediatric cardiology. Curr Opin Pediatr 2009, 21:585-593.
69. Jones RL Utility of dexrazoxane for the reduction of anthracycline-induced cardiotoxicity. Expert Rev Cardiovasc Ther 2008, 6:1311-1317.
70. van Dalen EC, Caron HN, Dickinson HO, Kremer LC Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev 2008, 2. CD003917.
71. Gaynon PS, Angiolillo AL, Carroll WL, et al. Long-term results of the children's cancer group studies for childhood acute lymphoblastic leukemia 1983-2002: a Children's Oncology Group Report. Leukemia 2010, 24:285-297. for the Children's Oncology Group.
72. Pui CH, Pei D, Sandlund JT, et al. Long-term results of St Jude Total Therapy Studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia. Leukemia 2010, 24:371-382.
73. Mitchell C, Richards S, Harrison CJ, Eden T Long-term follow-up of the United Kingdom medical research council protocols for childhood acute lymphoblastic leukaemia, 1980-2001. Leukemia 2010, 24:406-418.
74. Conter V, Aricò M, Basso G, et al. Long-term results of the Italian Association of Pediatric Hematology and Oncology (AIEOP) Studies 82, 87, 88, 91 and 95 for childhood acute lymphoblastic leukemia. Leukemia 2010, 24:255-264.
75. Möricke A, Zimmermann M, Reiter A, et al. Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia 2010, 24:265-284.
76. Kamps WA, van der Pal-de Bruin KM, Veerman AJ, Fiocco M, Bierings M, Pieters R Long-term results of Dutch Childhood Oncology Group studies for children with acute lymphoblastic leukemia from 1984 to 2004. Leukemia 2010, 24:309-319.
77. Tsurusawa M, Shimomura Y, Asami K, et al. Long-term results of the Japanese Childhood Cancer and Leukemia Study Group studies 811, 841, 874 and 911 on childhood acute lymphoblastic leukemia. Leukemia 2010, 24:335-344. for the Japanese Childhood Cancer and Leukemia Study Group.
78. Tebbi CK, London WB, Friedman D, et al. Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease. J Clin Oncol 2007, 25:493-500.
79. Lipshultz SE, Lipsitz SR, Orav EJ Dexrazoxane-associated risk for secondary malignancies in pediatric Hodgkin's disease: a claim without compelling evidence. J Clin Oncol 2007, 25:3179.
80. Hellmann K Dexrazoxane-associated risk for secondary malignancies in pediatric Hodgkin's disease: a claim without evidence. J Clin Oncol 2007, 25:4689-4690.
81. Le Delay M-C, Leblanc T, Shamsaldin A, et al. Risk of secondary leukemia after a solid tumor in childhood according to the dose of epidpodophyllotoxins and anthracyclines: a case-control study by the Societe Francaise d'Oncologic Pediatrique. J Clin Oncol 2003, 21:1074-1081.
82. Hijiya N, Ness KK, Ribeiro RC, Hudson MM Acute leukemia as a secondary malignancy in children and adolescents: current findings and issues. Cancer 2009, 115:23-35.
83. Bardi E, Bobok I, Olah AV, Kappelmayer J, Kiss C Anthracycline antibiotics induce acute renal tubular toxicity in children with cancer. Pathol Oncol Res 2007, 13:249-253.
84. Hu ST, Brandle E, Zbinden G Inhibition of cardiotoxic, nephrotoxic and neurotoxic effects of doxorubicin by ICRF-159. Pharmacology 1983, 26:210-220.
85. Thompson KL, Rosenzweig BA, Zhang J, et al. Early alterations in heart gene expression profiles associated with doxorubicin toxicity in rats. Cancer Chemother Pharmacol 2010, 66:304-314.
86. Nysom K, Colan SD, Lipshultz SE Late cardiotoxicity following anthracycline therapy for childhood cancer. Prog Pediatr Cardiol 1998, 8:121-138.
87. Sallan SE, Lipshultz SE Wise up: do not do it without protection!. Pediatr Blood Cancer 2005, 45:872-873.
88. Barry EV, Lipshultz SE, Sallan SE Anthracycline-induced cardiotoxicity: natural history, risk factors, and prevention. American Society of Clinical Oncology 2008 Educational Book 2008, 448-453. American Society of Clinical Oncology, Alexandria. R. Govindan (Ed.).
89. Scully R, Lipshultz SE Cardiovascular toxicity of antitumor drugs: dimensions of the problem in children. Cardiotoxicity of non-cardiovascular drugs 2010, 97-126. John Wiley & Sons, London. G. Minotti (Ed.).
90. Razoxane and dexrazoxane-two multifunctional agents. Experimental and clinical results 2010, Springer, London, New York. 1st edn. W. Rhomberg, K. Hellmann (Eds.).
91. Choi HS, Park ES, Kang HJ, et al. Dexrazoxane for preventing anthracycline cardiotoxicity in children with solid tumors. J Korean Med Sci 2010, 25:1336-1342.